Next Generation Labs Granted Australian Patent for the Use of TFN® Combinational R- and S-Isomer Synthetic Nicotine in Tobacco Cessation Products
Share Article
The use of combinational and variable isomeric ratios of R and S synthetic nicotine may ultimately assist adults in quitting or reducing their overall dependence on tobacco.
TFN
...future combinational R- and S-isomer nicotine formulations may prove to be less addictive than natural or biosimilar standalone S-isomer nicotine, and could potentially help achieve the broader public health goal of providing adult consumers with a satisfying, but non-addictive form of nicotine
SAN DIEGO (PRWEB)
July 22, 2021
Next Generation Labs LLC, the company that was first to manufacture and market bulk high quality synthetic R-S, S- and R-isomer nicotine under the TFN® brand, is pleased to announce that the Company has been granted an Australian patent (IP Australia #2016381372) for its innovative use of combinational ratios of synthetic R- and S-isomer nicotine in tobacco cessation products.